Capricor Therapeutics Financials - Benzinga

Capricor Therapeutics Inc

CAPRNASDAQ

Trade with Public

Trade with Public

$6.65

2.4457.96%

At close: Aug 14, 5:00 PM EST

$6.50

-0.15-2.26%

After Hours: 7:59 PM EST

PRO

Why Is It Moving?™:Capricor Therapeutics shares are trading higher after the company reported ...

Earnings: Q2 2026 Earnings were released on Thu Aug 13th, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 1 day ago

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Capricor Therapeutics Financials

Capricor Therapeutics (CAPR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval

Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.

Vandana Singh

Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why

Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.

Mohd Haider

PRO
Capricor Therapeutics Q2 EPS $(0.70) Misses $(0.58) Estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.58) by 20.69 percent. This is a 22.81 percent decrease over losses of $(0.57) per

Benzinga Newsdesk

PRO
Capricor Therapeutics Q1 EPS $(0.59) Misses $(0.50) Estimate

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
Capricor Therapeutics Believes That, Based On The Current Operating Plan And Financial Resources, Its Available Cash, Cash Equivalents And Marketable Securities Will Be Sufficient To Cover Anticipated Expenses And Capital Requirements Through 2027

Expectation Excludes Any Additional Potential Milestone Payments Under The Commercialization And Distribution Agreements With Nippon Shinyaku, As Well As Any Strategic Use Of Capital Not Currently In The Company's Base

Benzinga Newsdesk